On October 21, 2026 Foundation Medicine, Inc., a global, patient-focused precision medicine company, reported the acceptance of 12 abstracts for presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, scheduled for October 23-27, 2026, in Madrid, Spain. These presentations cover key topics such as MTAP loss, the clinical impact of clonal hematopoiesis (CH), and the expanded utility of circulating tumor DNA (ctDNA) tumor fraction.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to 10 poster presentations, Foundation Medicine’s research will be featured in two Rapid Oral Sessions:

2218RO – Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC)
Friday, October 23 at 13:00 CEST in Bilbao Auditorium – Hall 3
2219RO – Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC)
Friday, October 23 at 13:00 CEST in Bilbao Auditorium – Hall 3
Foundation Medicine will also host a series of expert-led booth talks in its booth 1030 in Hall 10:

Saturday, October 24
13:00 – 13:15 CEST – Don’t Miss the Loss: Unlocking MTAP, PTEN & Others Through Robust Copy Number Detection
13:25 – 13:40 CEST – Breaking the Sensitivity Floor: The Science of Ultra-Sensitive MRD
13:50 – 14:05 CEST – Detect MTAP Loss More Often in Your Clinical Trials: Don’t Miss the Signal
14:15 – 14:30 CEST – Don’t Miss Fusions and Complex Variants with FoundationOneRNA
Sunday, October 25
13:00 – 13:15 CET – Translating Ultra-Sensitive MRD to Clinical Practice: Detection and Monitoring of ctDNA Using Structural Variants
13:30 – 13:45 CET – Don’t Miss the Loss: Unlocking MTAP, PTEN & Others Through Robust Copy Number Detection
14:00 – 14:15 CET – Redefining the Standard in MRD: Structural Variants & Digital PCR for Ultra Sensitivity & High Specificity
Monday, October 26
13:00 – 13:15 CET- The Role of Longitudinal ctDNA Testing in Early and Advanced Stage Cancer
13:30 – 13:45 CET – Don’t Miss the Loss: Unlocking MTAP, PTEN & Others Through Robust Copy Number Detection
14:00 – 14:15 CET – HRD Signature Without Limits: Go Beyond Ovarian
To learn more, visit Foundation Medicine in person at booth 1030 in Hall 10 or book a meeting at View Source

Full List of Foundation Medicine’s Abstracts at ESMO (Free ESMO Whitepaper) Congress 2026

Presentation Number

Title

Product

Friday, October 23

2218RO

Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC)

FoundationOneLiquid CDx

2219RO

Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC)

FoundationOne Liquid CDx, FoundationOneMonitor

4294P

The Tumor-Agnostic (TA) Therapy Biomarker Landscape: Established and Emerging Markers Across 385,420 Solid Tumors

FoundationOneCDx

4304P

Comprehensive Genomic Profiling in Lacrimal Duct Carcinoma Reveals HER2-Driven Biology and Emerging Therapeutic Targets

FoundationOne CDx

4762P

Homologous Recombination Signature (HRDsig) in Adenocarcinoma (ACB) and Urachal Carcinoma (UrCA) of the Bladder: Implications for PARP Inhibitor (PARPi) Treatment

FoundationOne CDx

4308P

Genomic Landscape of KRAS G12D Mutant Non-Small Cell Lung Cancer (NSCLC) and Comparison with KRAS non-G12D Mutant and KRAS Wild Type Cases

FoundationOne CDx

4372P

MTAP Loss and HPV Status in Head and Neck Squamous Cell Carcinoma (HNSCC): A Genomic Landscape Study

FoundationOne CDx

2232P

Longitudinal ctDNA tumor fraction (TF) as a prognostic biomarker in bone-dominant metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 ± olaparib: Results from the phase 2 COMRADE trial

FoundationOne Liquid CDx,

FoundationOne Monitor

4750P

Overall survival (OS) and mature safety results of SURE-02, a phase 2 study of neoadjuvant Sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant Pembro, in patients with muscle-invasive bladder cancer (MIBC)

N/A

4283P

ctDNA tumor fraction captures tumor biology and predicts resistance to systemic therapy across solid tumors and NSCLC

FoundationOne Liquid CDx

Monday, October 26

3765P

Homologous Recombination Signature (HRDsig) in Angiosarcoma (AngSarc)

FoundationOne CDx

2628P

Genomic and Biomarker Landscape of MTAP loss/KRAS G12D mutant vs. MTAP loss/KRAS non-mutated Advanced NSCLC

FoundationOne CDx

(Press release, Foundation Medicine, OCT 21, 2026, View Source [SID1234673653])

On October 21, 2026 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, reported the presentation of a poster detailing the design of its planned Phase 2 clinical trial evaluating epetraborole in patients with polycythemia vera (PV) at the 18th International Congress on Myeloproliferative Neoplasms being held October 29-30, 2026 in Brooklyn, New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Session Details
Title: Phase 2 Study of Oral Epetraborole for Treatment of Phlebotomy-Dependent PV
Date: Thursday, October 29, 2026
Time: 5:45-7:15pm ET
Poster number: 148

(Press release, AN2 Therapeutics, OCT 21, 2026, View Source [SID1234673652])

On October 21, 2026 Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis, a suite of artificial intelligence (AI) powered Software as Medical Devices (SaMD) for early cancer detection and diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, reported that it will participate in the ESMO (Free ESMO Whitepaper) Congress 2026, taking place October 23-27, 2026, at IFEMA in Madrid, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Median’s iCRO team will welcome attendees at booth #1098, Hall 10, from October 23 to 26, from 10:00 a.m. to 6:30 p.m. (technical exhibition hours), where it will showcase the latest advances in its central imaging and AI-powered image analysis services for oncology clinical trials.

The Company will host an interactive session at its booth exploring practical insights from the implementation of RANO 2.0, the updated response assessment framework for neuro-oncology, in central imaging review:

RANO 2.0 in Central Imaging Review: Driving Success in Neuro-Oncology Trials
Sunday, October 25 | 12:00 p.m.-12:30 p.m. Presenters: Antoine Iannessi, VP Medical Affairs, iCRO, Median Technologies, and Anne-Sophie Auroux, VP Operations, iCRO, Median Technologies
The Company will also present the ePoster " Prevalence of Emphysema in Patients with Non Small Lung Cancer (NSCLC)" (2560eP).

(Press release, MEDIAN Technologies, OCT 21, 2026, View Source [SID1234673651])

On October 21, 2026 Akeso, Inc. (HKEX: 9926.HK) reported that Summit Therapeutics Inc. (NASDAQ: SMMT), its global partner for ivonescimab, has entered into a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab in a registration-enabling Phase II/III study in biliary tract cancer (BTC). The new study, EA2251 (NCT07765433), is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab plus chemotherapy in the first-line treatment of patients with advanced BTC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This marks the 7th international registrational Phase II/III clinical trial for ivonescimab. Previously, the Phase III HARMONi-GI1 study conducted by Akeso in China, evaluating ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for patients with BTC, achieved a positive overall survival (OS) result that was both statistically significant and clinically meaningful.

"Biliary tract cancer is often diagnosed at an advanced stage, and despite recent progress, there is a need for more effective first-line options that can extend survival and improve disease control," said lead investigator Deirdre J. Cohen, MD, MS, Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, Director of the Gastrointestinal Oncology Program for the Mount Sinai Health System and Co-Director of the Center of Excellence for Pancreatic Cancer at the Mount Sinai Tisch Cancer Center. "EA2251 will explore a novel therapeutic approach in the front-line setting by evaluating ivonescimab with chemotherapy against current immunotherapy-based standards of care."

"We are delighted to see the global clinical development of ivonescimab further expand into the field of biliary tract cancer. Against the background of the positive OS results from the Phase III HARMONi-GI1 study of ivonescimab plus chemotherapy versus durvalumab plus chemotherapy, the advancement of the Phase III EA2251 study by a leading cooperative oncology group in the United States further strengthens our confidence in achieving global success," said Dr. Michelle Xia, Founder, Chairwoman, President and Chief Executive Officer of Akeso. "We look forward to the progress of ivonescimab’s registrational clinical development worldwide and its potential to become a superior treatment option for patients with biliary tract cancer globally as early as possible."

"We are honored to collaborate with ECOG-ACRIN on EA2251 as we continue to expand the development program for ivonescimab in areas of meaningful unmet need," said Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics. "The sponsorship and conduct of this registration-enabling study by a leading cooperative oncology group underscores the scientific interest in evaluating ivonescimab in difficult-to-treat cancers, including BTC, and supports Summit’s commitment to building a robust body of clinical evidence across multiple tumor types and treatment settings."

EA2251 is the second Phase III registrational clinical study of ivonescimab in BTC. Detailed results from HARMONi-GI1 (AK112-309), which evaluated ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with BTC, will be presented at the European Society for Medical Oncology 2026 Congress (ESMO 2026) on Sunday, October 25, during the Presidential Symposium from 4:30pm – 6:15pm CET (11:30am – 1:15pm EDT).

(Press release, Akeso Biopharma, OCT 21, 2026, View Source [SID1234673648])

On October 21, 2026 Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalized immunotherapy for cancer (PIC), reported the initiation of its Phase 2 randomized clinical trial (NCT07722741) in patients with high-risk hepatocellular carcinoma (HCC, liver cancer) who have undergone resection with curative intent. The IMPACT31 trial is a multi-center global trial with a planned enrollment of 90 patients. PICs are targeted treatments that train a patient’s immune system to attack unique genetic mutations (neoantigens) found only in their specific tumor cells while sparing healthy tissue. The trial evaluates the efficacy of Geneos’ PIC (GNOS-PV02), compared to the current standard of care (active surveillance) in high-risk patients following surgery.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additionally, the company announced the appointment of Julie Rosenberg, MD, as Chief Medical Officer. Dr. Rosenberg has more than two decades of leadership and drug development experience in the biopharmaceutical industry.

"We are thrilled to welcome Julie to our leadership team to drive the IMPACT31 trial and advance the development of Geneos’ tumor-agnostic immunotherapy platform and clinical pipeline. Her experience and well-developed network in clinical development within biopharma will be invaluable in the coming years as Geneos advances toward late-stage clinical development," said Niranjan Sardesei, Ph.D., President & CEO of Geneos. "We have reported clinical safety and efficacy in our early Phase 1/2 trials, in two distinct cancers, by treating patients with advanced HCC who failed or were intolerant to first-line therapy and, also in the adjuvant setting in glioblastoma (brain cancer). These are two hard-to-treat, immune-excluded, cold cancers, which have historically proved unresponsive to immunotherapy. We are excited to bring the possibility of long-term clinical benefit to high-risk HCC patients in this randomized controlled trial."

Dr. Rosenberg completed her pediatric residency and hematology/oncology training at Baylor College of Medicine and has held leadership roles at major pharmaceutical companies – Boehringer Ingelheim, Bristol Myers Squibb, Bayer Healthcare and Pfizer. She most recently served as Head of the Oncology Franchise for Linical, a mid-sized, global, Contract Research Organization. Dr. Rosenberg joins Geneos at a pivotal stage, bringing her deep leadership and executive experience related to trial design, clinical development pathways, pharmacovigilance, medical strategy, operational efficiencies, regulatory submissions, and more.

"The clinical data to date and the Geneos DNA vaccine platform are extremely compelling," said Dr. Rosenberg. "I’m delighted to join Geneos at this critical time and value the opportunity to further augment the clinical programs with the hope of seeing truly differentiating data for hard-to-treat cancers."

The IMPACT31 trial will enroll patients at clinical sites in the US and in countries in the Asia-Pacific region.

"Initiating the IMPACT31 trial is an important milestone in our effort to improve outcomes for patients with HCC," said Mark Yarchoan, MD, Professor of Medicine at Johns Hopkins University, and Clinical Investigator on the IMPACT31 trial. "Most patients with HCC, particularly those with high-risk features at the time of surgery, experience disease recurrence following curative-intent resection, and there are currently no approved or effective therapies to prevent recurrence. IMPACT31 builds on encouraging safety and preliminary efficacy data from a prior Phase 1/2 trial in patients with advanced HCC, published in Nature Medicine in 2024, as well as recent successes with personalized cancer vaccines in other tumor types. We are hopeful that this approach will offer a new strategy to reduce recurrence and improve long-term outcomes for patients with HCC."

About personalized DNA immunotherapy for cancer (PIC)

PICs are patient-specific treatments based on DNA plasmids that encode up to 40 tumor neoantigens on a single DNA plasmid. A patient’s tumor is sequenced to identify the neoantigens used to develop a personalized DNA cancer vaccine. Treatment with PICs trains the patient’s immune cells to produce cancer targeting CD4 and CD8 T cells that destroy the cancer cells. PICs mechanism of action is cancer agnostic, and the platform supports seamless expansion into other cancers beyond HCC and glioblastoma.

About GT-31 Phase 2b Randomized Controlled Trial

The Phase 2b trial (ClinicalTrials.gov identifier: NCT07722741) is a multi-center, open-label, two arm randomized controlled study that evaluates the personalized DNA vaccine versus active surveillance, the current standard of care, in patients with high-risk HCC post tumor resection. The trial design of PIC monotherapy versus active surveillance in the adjuvant setting will both leverage and highlight PIC’s patient-specific mechanism of action for treating patients with cold, low tumor mutational burden cancers.

(Press release, Geneos Therapeutics, OCT 21, 2026, View Source [SID1234673647])